• Home
  • NEW DAY MEDICINE
  • 8 (82) 2025
  • 60 -8 (82) 2025 - Aripov A.N., Tursunov J.Kh. - MODERN TRENDS IN PLATELETS, INFLAMMATION, AND PERSONALIZED THERAPY IN CARDIOVASCULAR DISEASES

60 -8 (82) 2025 - Aripov A.N., Tursunov J.Kh. - MODERN TRENDS IN PLATELETS, INFLAMMATION, AND PERSONALIZED THERAPY IN CARDIOVASCULAR DISEASES

MODERN TRENDS IN PLATELETS, INFLAMMATION, AND PERSONALIZED THERAPY IN CARDIOVASCULAR DISEASES

Aripov A.N. - Head of the Clinical Diagnostic Laboratory Department, Republican Specialized Scientific-Practical Medical Center of Pediatrics

Tursunov J.Kh. - Head of the Cardiology Department, Andijan Regional Multidisciplinary Medical Center, PhD

Resume

Cardiovascular diseases (CVD) remain among the leading causes of mortality and morbidity worldwide. Contemporary clinical research and guidelines indicate that the pathogenesis of CVD is determined not only by lipid accumulation but also by inflammation, platelet activity, and immune response. This article provides an expanded review of the biological and clinical mechanisms of restenosis, no-reflow phenomenon, and stent thrombosis after percutaneous coronary interventions. Dual antiplatelet therapy duration, the efficacy of novel antiplatelet agents, prognostic significance of inflammatory biomarkers (CRP, IL-6, VCAM-1), and the importance of personalized therapeutic strategies are critically analyzed. The review concludes that effective CVD management requires a comprehensive approach integrating prevention, personalized treatment, and complication control.

Keywords: cardiovascular diseases, platelets, percutaneous coronary interventions, restenosis, antiplatelet therapy, Dual antiplatelet therapy, inflammation, biomarkers, personalized therapy.

First page

339

Last page

342

For citation:Aripov A.N., Tursunov J.Kh. - MODERN TRENDS IN PLATELETS, INFLAMMATION, AND PERSONALIZED THERAPY IN CARDIOVASCULAR DISEASES//New Day in Medicine 8(82)2025 339-342 https://newdayworldmedicine.com/en/new_day_medicine/8-82-2025

List of References

  1. Toutouzas, K., A. Colombo, and C. Stefanadis, Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J, 2004. 25(19): p. 1679-87.
  2. Ridker, P.M., et al., Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 2017. 377(12): p. 1119-1131.
  3. Levine, G., et al., 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. The Journal of Thoracic and Cardiovascular Surgery, 2016. 152: p. 1243-1275.
  4. Neumann, F.J., et al., 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J, 2019. 40(2): p. 87-165.
  5. Capodanno, D. and D.J. Angiolillo, Personalised antiplatelet therapies for coronary artery disease: what the future holds. 2023. 44(32): p. 3059-3072.
  6. Wallentin, L., et al., Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009. 361(11): p. 1045-57.
  7. Harrison, R.W., et al., Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol, 2013. 111(2): p. 178-84.
  8. van der Meijden, P.E.J. and J.W.M. Heemskerk, Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol, 2019. 16(3): p. 166-179.
  9. Piepoli, M.F., et al., 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Rev Esp Cardiol (Engl Ed), 2016. 69(10): p. 939.
  10. Wolf, D. and K. Ley, [Immunity and inflammation in atherosclerosis]. Herz, 2019. 44(2): p. 107-120.
  11. Franchi, F. and D.J. Angiolillo, Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol, 2015. 12(1): p. 30-47.
  12. Collet, J.P., et al., 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J, 2021. 42(14): p. 1289-1367.
  13. Costa, F., et al., Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol, 2019. 73(7): p. 741-754.
  14. Vorpahl, M., et al., Pathobiology of stent thrombosis after drug-eluting stent implantation. Curr Pharm Des, 2010. 16(36): p. 4064-71.
  15. Troncoso, M.F., et al., VCAM-1 as a predictor biomarker in cardiovascular disease. Biochim Biophys Acta Mol Basis Dis, 2021. 1867(9): p. 166170.

    file

    download